- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03855371
Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS (PANDA-T0)
Combination of Decitabine and ATO to Treat AML/MDS Expressing a Classified Type of Mutant p53
TP53 mutation is commonly associated with poor cancer patient prognosis yet no mutant p53 (mp53)-targeting regimen was clinically established. Here the investigators try to evaluate the side effect and treatment potential of DAC+ATO in p53 mutated high-risk AML/MDS patients.
About 200 AML/MDS patients will be sequenced for TP53 sequence before recruitment. The investigators estimated about 5 patients, based on the reported p53 mutation frequency in AML/MDS, will be p53-mutated. In the trial, the investigators will selectively recruit the mp53 AML/MDS patients that are predicted to respond to DAC+ATO regimen with highest chance (based on the relevant basic studies).
The investigators designate mutant p53-based clinical trials as 'PANDA (P53 AND Arsenic)-Trials'.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
TP53 mutation is commonly associated with poor cancer patient prognosis yet no mutant p53 (mp53)-targeting regimen was clinically established. In two independent clinical trials reported recently, DNA demethylating drug Decitabine (DAC) treatment yielded a surprisingly high rate of complete remission (CR) in mp53-expressing myelodysplastic syndromes (MDS) patients and acute myeloid leukemia (AML) patients. Notably, all of the mp53-expressing patients in the two clinical studies, despite of CR, relapsed quickly. This was attributed to a failure in thoroughly clearing all leukemia-specific mutations and the preexisting mp53 subclone outgrew in all of the relapse patients. Indeed, The investigators also found p53 dysfunctional cells quickly develop a DAC resistance mechanism in cultured tissue (unpublished data). Meanwhile, the investigators found arsenic trioxide (ATO) selectively inhibit p53-mutated cells involving mutant p53 reactivation and mutant p53 degradation (presumably mediated by upregulated mdm2 and RCHY1/Pirh2 through reactivated mutant p53). In addition, DAC and ATO show synergy in inhibiting p53-mutated cells.
In current phase I trial, the investigators try to evaluate the side effect and treatment potential of DAC+ATO in p53 mutated high-risk MDS patients. About 200 AML/MDS patients will be recruited for TP53 sequencing before being trialed. The investigators estimated about 50 patients, based on p53 mutation frequency in AML/MDS, will be sequenced to be mp53-positive. The mp53-positive AML/MDS patients are known to have an extremely poor prognosis. The investigators will select high-risk mp53 MDS patients that are predicted to respond to DAC+ATO with highest chance based on our relevant basic studies.
The other participants (free of p53 mutation) will be excluded from the trial.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Min Lu, PhD
- Phone Number: 610805 0086-21-64370045
- Email: min.lu@shsmu.edu.cn
Study Contact Backup
- Name: Sujiang Zhang, MD, PhD
- Email: zbruce.zhang@hotmail.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200025
- Recruiting
- Hematological department, Shanghai Institute of Hematology, Ruijin Hospital
-
Contact:
- Min Lu, PhD
- Phone Number: 610805 0086-21-64370045
- Email: min.lu@shsmu.edu.cn
-
Contact:
- Sujiang Zhang, PhD
- Email: zbruce.zhang@hotmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Occurrence of p53 mutants that are predicted to respond to ATO+DAC with highest chance
- Patients newly diagnosed with myelodysplastic syndromes.
- ECOG Performance status ≤ 3.
- Aged from 18 to 75.
- Active bone marrow hyperplasia indicated by morphology
- Normal liver and renal function, bilirubin ≤35μmol/L, ASL/ALT lower than 2xULN, creatinine level ≤150μmol/L
- Normal cardiac function
- Written Informed consent.
Exclusion Criteria:
- Patients previously treated.
- Confirmed CNS involvement.
- Abnormal liver function which does not meet the inclusion criteria.
- Severe cardiac diseases including myocardial infarction or heart insufficiency.
- QT interval ≥450ms on ECG.
- With other visceral malignancy.
- Active tuberculosis or HIV(+).
- Patients with pregnancy or lactation.
- Allergic or significantly contraindicated to any drugs involved in intervention.
- Significantly contraindicated to HMA chemotherapy.
- ECOG performance status ≥3, CCI >1, ADL <100.
- Unable to understand or follow the study protocol.
- Previous intolerance or allergy history to similar drugs.
- Aged <18 yrs or >75yrs
- MDS patients previously treated with decitabine.
- Participation at same time in another study in which investigational drugs are used.
- Any other conditions interfering the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Decitabine plus arsenic trioxide
decitabine: 20mg/m2/d, intravenously, d1-d5, q4w arsenic trioxide: 0.16mg/kg/d, intravenously, d1-d5, q4w(maximum dose: 10mg/d)
|
20mg/m2/d, intravenously, d1-d5, q4w
Other Names:
0.16mg/kg/d, intravenously, d1-d5, q4w(maximum dose: 10mg/d)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
side effect
Time Frame: during the whole treatment
|
evaluate the side effects of current regimen
|
during the whole treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate
Time Frame: at the end of cycle 4 (each cycle is 28 days)
|
Partial response (PR) + complete response (CR) rate
|
at the end of cycle 4 (each cycle is 28 days)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sujiang Zhang, MD, PhD, Shanghai Institute of Hematology, Ruijin Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Mutant p53-based trial
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on P53 Mutation
-
Li JunminUnknownAcute Myeloid Leukemia | P53 MutationChina
-
First Affiliated Hospital of Jinan UniversityRuijin HospitalRecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | P53 Mutation | Myeloid Malignancy | Temperature-Sensitive p53 Mutation | Sodium StibogluconateChina
-
AstraZenecaCompletedOvarian, Fallopian Tube, Peritoneal Cancer, P53 MutationUnited States, Canada, Netherlands
-
Moy-Fincher-Chipps Facial Plastics and DermatologyUnknown
-
Li JunminWithdrawnMyelodysplastic Syndromes | P53 MutationChina
-
Shanghai Changzheng HospitalUnknownRefractory Cancer | Arsenic Trioxide | p53 Mutations | Intractable CancerChina
-
Novartis PharmaceuticalsCompletedSolid Tumor With p53 Wild Type StatusFrance, Germany, Singapore, Switzerland, United States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedMitochondrial Disorders | Li-Fraumeni Syndrome | Carriers of p53 MutationUnited States
-
Federal University of São PauloCompletedPhotoaging | Epidermal p53 ExpressionBrazil
-
Pamela MunsterNational Cancer Institute (NCI)Not yet recruitingBRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | ATM Gene Mutation | BRCA Mutation | Checkpoint Kinase 2 Gene MutationUnited States
Clinical Trials on Decitabine
-
Otsuka Beijing Research InstituteRecruitingMyelodysplastic SyndromesChina
-
Chinese PLA General HospitalRecruitingHodgkin Lymphoma | Anti-PD-1 Antibody ResistantChina
-
Astex Pharmaceuticals, Inc.CompletedAcute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic LeukemiaUnited States, Canada, Spain, Hungary, Austria, Czechia, France, Germany, Italy, United Kingdom
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkRecruitingCastration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8United States
-
M.D. Anderson Cancer CenterGenentech, Inc.; Astex Pharmaceuticals, Inc.RecruitingChronic Myelomonocytic Leukemia | Myelodysplastic SyndromeUnited States
-
Shandong UniversityUnknownMyelodysplastic SyndromesChina
-
M.D. Anderson Cancer CenterRecruitingAcute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent Acute Biphenotypic Leukemia | Refractory Acute Biphenotypic LeukemiaUnited States
-
Eisai Inc.TerminatedMyelodysplastic SyndromesUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Astex Pharmaceuticals, Inc.RecruitingChronic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome Positive | BCR-ABL1 Positive Chronic Myelogenous Leukemia | BCR-ABL1 PositiveUnited States